Structure Therapeutics Inc. (GPCR) delivered the kind of clinical trial results that make biotech investors very happy. The clinical-stage biopharmaceutical company announced positive topline data from its weight loss drug trial Monday, sending shares into orbit and touching a 52-week high of $94.90.
What The Data Shows: Aleniglipron, Structure's once-daily oral pill that targets the GLP-1 receptor, achieved clinically meaningful and statistically significant results. In one study, patients taking the drug saw placebo-adjusted mean weight loss of up to 15.3%, translating to about 35.5 pounds.
That's the kind of number that gets attention in the weight loss space. But here's what might matter just as much: the safety profile looked good. Structure Therapeutics emphasized that aleniglipron demonstrated a compelling off-target safety profile, clearing the path for Phase 3 clinical development.
"The topline results presented today show that aleniglipron is differentiated and delivered clinically meaningful, competitive and dose-dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people," said Raymond Stevens, CEO of Structure Therapeutics.
The Bigger Picture: The weight loss drug market has exploded recently. Morgan Stanley Research projects the global obesity drug market could hit $150 billion by 2035. For context, the market generated about $15 billion in sales in 2024. That's a tenfold increase in just over a decade.
GPCR Price Action: Structure Therapeutics shares were up 96.64%, trading at $67.93 at the time of publication.
